# OnCo record keynote-a18 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-a18/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-a18", "NCT04221945" ;
  schema:name "KEYNOTE-A18 / ENGOT-cx11 / GOG-3047"@en ;
  schema:description "Adding immunotherapy to curative chemoradiation for locally advanced cervical cancer improved both control and survival, the first such advance in two decades."@en ;
  schema:url <https://onco.cc/trials/keynote-a18/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04221945>, <https://doi.org/10.1016/S0140-6736(24)00317-9>, <https://doi.org/10.1016/S0140-6736(24)01808-7> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2020-05-12" ;
  onco:cancers <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/locally-advanced-cervical-cancer/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/gog-foundation/> ;
  onco:people <https://onco.cc/people/domenica-lorusso/>, <https://onco.cc/people/bradley-monk/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-a18-pfs-lancet-2024/>, <https://onco.cc/key-papers/paper-keynote-a18-os-lancet-2024/> .